Literature DB >> 23813644

Are ongoing trials on hematologic malignancies still excluding older subjects?

Antonio Cherubini, Francesca Pierri, Beatrice Gasperini, Elisa Zengarini, Annarita Cerenzia, Elisabetta Bonifacio, Flavio Falcinelli, Fabrizia Lattanzio.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23813644      PMCID： PMC3696593          DOI： 10.3324/haematol.2013.087601

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study.

Authors:  Peter Crome; Frank Lally; Antonio Cherubini; Joaquim Oristrell; Andrew D Beswick; A Mark Clarfield; Cees Hertogh; Vita Lesauskaite; Gabriel I Prada; Katarzyna Szczerbińska; Eva Topinkova; Judith Sinclair-Cohen; David Edbrooke; Gary Mills
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 2.  The epidemiology of myelodysplastic syndromes.

Authors:  Mikkael A Sekeres
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

3.  The persistent exclusion of older patients from ongoing clinical trials regarding heart failure.

Authors:  Antonio Cherubini; Joaquim Oristrell; Xavier Pla; Carmelinda Ruggiero; Roberta Ferretti; Germán Diestre; A Mark Clarfield; Peter Crome; Cees Hertogh; Vita Lesauskaite; Gabriel-Ioan Prada; Katarzyna Szczerbinska; Eva Topinkova; Judith Sinclair-Cohen; David Edbrooke; Gary H Mills
Journal:  Arch Intern Med       Date:  2011-03-28

4.  Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Authors:  Peter M Fayers; Antonio Palumbo; Cyrille Hulin; Anders Waage; Pierre Wijermans; Meral Beksaç; Sara Bringhen; Jean-Yves Mary; Peter Gimsing; Fabian Termorshuizen; Rauf Haznedar; Tommaso Caravita; Philippe Moreau; Ingemar Turesson; Pellegrino Musto; Lotfi Benboubker; Martijn Schaafsma; Pieter Sonneveld; Thierry Facon
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

Review 5.  Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Authors:  Antonio Palumbo; Sara Bringhen; Heinz Ludwig; Meletios A Dimopoulos; Joan Bladé; Maria V Mateos; Laura Rosiñol; Mario Boccadoro; Michele Cavo; Henk Lokhorst; Sonja Zweegman; Evangelos Terpos; Faith Davies; Christoph Driessen; Peter Gimsing; Martin Gramatzki; Roman Hàjek; Hans E Johnsen; Fernando Leal Da Costa; Orhan Sezer; Andrew Spencer; Meral Beksac; Gareth Morgan; Hermann Einsele; Jesus F San Miguel; Pieter Sonneveld
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

6.  Cancer rates, medical comorbidities, and treatment modalities in the oldest patients.

Authors:  John E Zeber; Laurel A Copeland; Brandon J Hosek; Anand B Karnad; Valerie A Lawrence; Sandra E Sanchez-Reilly
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-19       Impact factor: 6.312

7.  Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.

Authors:  M Rohrbacher; U Berger; A Hochhaus; G Metzgeroth; K Adam; T Lahaye; S Saussele; M C Müller; J Hasford; H Heimpel; R Hehlmann
Journal:  Leukemia       Date:  2008-09-11       Impact factor: 11.528

Review 8.  Multiple myeloma in elderly patients: presenting features and outcome.

Authors:  P Rodon; C Linassier; J B Gauvain; L Benboubker; P Goupille; M Maigre; F Luthier; J Dugay; V Lucas; P Colombat
Journal:  Eur J Haematol       Date:  2001-01       Impact factor: 2.997

9.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

10.  Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.

Authors:  Michael Schaapveld; Otto Visser; Sabine Siesling; Cees G Schaar; Sonja Zweegman; Edo Vellenga
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162
View more
  7 in total

Review 1.  Frailty in Hematologic Malignancy.

Authors:  Thuy T Koll; Ashley E Rosko
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

2.  Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.

Authors:  Adam J Olszewski; Thomas Ollila; John L Reagan
Journal:  Br J Haematol       Date:  2018-04-24       Impact factor: 6.998

Review 3.  Nuances in the Management of Older People With Multiple Myeloma.

Authors:  Charlotte Pawlyn; Francesca Gay; Alessandra Larocca; Vivek Roy; Sikander Ailawadhi
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

4.  Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.

Authors:  Alix Augustin; Steven Le Gouill; Rémy Gressin; Aurélie Bertaut; Alain Monnereau; Anne-Sophie Woronoff; Brigitte Trétarre; Patricia Delafosse; Xavier Troussard; Anne Moreau; Olivier Hermine; Marc Maynadié
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-11       Impact factor: 4.553

Review 5.  Multiple myeloma in the older adult: better prospects, more challenges.

Authors:  Tanya M Wildes; Ashley Rosko; Sascha A Tuchman
Journal:  J Clin Oncol       Date:  2014-08-20       Impact factor: 44.544

6.  Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Authors:  David P Steensma; Medrdad Abedi; Rafael Bejar; Christopher R Cogle; Kathryn Foucar; Guillermo Garcia-Manero; Tracy I George; David Grinblatt; Rami Komrokji; Xiaomei Ma; Jaroslaw Maciejewski; Daniel A Pollyea; Michael R Savona; Bart Scott; Mikkael A Sekeres; Michael A Thompson; Arlene S Swern; Melissa Nifenecker; Mary M Sugrue; Harry Erba
Journal:  BMC Cancer       Date:  2016-08-19       Impact factor: 4.430

7.  Willingness to Participate in Health Research Among Community-Dwelling Middle-Aged and Older Adults: Does Race/Ethnicity Matter?

Authors:  Sadaf Arefi Milani; Michael Swain; Ayodeji Otufowora; Linda B Cottler; Catherine W Striley
Journal:  J Racial Ethn Health Disparities       Date:  2020-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.